The prognostic value of weight loss during radiotherapy among patients with nasopharyngeal carcinoma: a large-scale cohort study

Ya-Nan Jin1,2†, Tian-Liang Xia3†, Dong-Mei Mai4†, Ji-Jin Yao2, Chang Jiang1, Wen-Zhuo He1* and Liang-Ping Xia1*

Abstract

Background: We aim to investigate the prognostic value of weight loss during radiotherapy (RT) among patients with nasopharyngeal carcinoma (NPC).

Methods: A total of 1149 NPC patients who received radical RT were retrospectively analyzed. Patients’ weight were measured at initiation of RT (W_{Pre-RT}) and every week during RT (W_{RT1,2,3,4,5,6,7}). Percentage of weight loss (PWL) at 1st, 2nd, 3rd, 4th, 5th, 6th, and 7th week of RT (RT-PWL1,2,3,4,5,6,7) were calculated using the following equation: (W_{Pre-RT} - W_{RT1,2,3,4,5,6,7})/W_{Pre-RT} × 100%. The optimal threshold of RT-PWL7 was determined by recursive partitioning analyses (RPAs). Our endpoints included disease-free survival (DFS), overall survival (OS), distant metastasis-free survival (DMFS), and locoregional relapse-free survival (LRRFS).

Results: The median RT-PWLs were 0, 0, 1.5, 2.9, 4.1, 5.5, 6.6% at 1st, 2nd, 3rd, 4th, 5th, 6th, and 7th week of RT, respectively. RT-PWL7 optimal threshold with respect to DFS was 5.3% based on RPAs. Therefore, a consistent threshold of 5% (<5% vs ≥5%) was selected to classify NPC patients into low RT-PWL7 and high RT-PWL7 groups for survival analysis. Compared to high RT-PWL7 (≥5%), patients with low RT-PWL7 (<5%) had significantly better ten-year DFS (61.2% vs 78.8%; P < 0.001), OS (70.1% vs 86.6%; P < 0.001), and DMFS (80.2% vs 88.5%; P = 0.007). However, no difference was observed between LRRFS groups (91.7% vs 94.3%; P = 0.173). In multivariate analysis, high RT-PWL7 was an independent risk factor for DFS (HR, 1.56; 95%CI, 1.19-2.03; P = 0.001), OS (HR, 1.54; 95%CI, 1.11-2.15; P = 0.011), and DMFS (HR, 1.47; 95%CI, 1.03-2.10; P = 0.033) in patients with NPC. In addition, treatment strategy, plasma Epstein-Barr virus DNA, and N stage were associated with weight loss.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Nasopharyngeal carcinoma (NPC), an epithelial malignancy that is distinguished from other head and neck cancers, is highly prevalent in southern China [1]. The main treatment for NPC is radiotherapy (RT) due to anatomical restrictions and radio-sensitivity. Over the past decade, advances in imaging techniques, chemotherapy, and radiation technology contributed to improved NPC survival. However, 20–30% of patients still die because of NPC recurrence [2, 3]. Therefore, efforts to identify modifiable risk factors can potentially provide new insights on developing clinical intervention for increasing long-term survival.

Patients diagnosed with head and neck cancers often experience weight loss during RT due to acute toxicity, such as mucositis, dysgeusia, xerostomia, and nausea [4–7]. Previous studies [8, 9] have estimated the incidences of weight loss to range from 40 to 90%, especially among NPC patients where rates were high. Substantial weight loss during treatment was significantly associated with poor survival among NPC patients [10–13]. Monitoring decreasing weight during RT will allow for clinicians to evaluate the current treatment plan effectiveness for NPC [14]. Knowing the influencing factors for weight loss during RT is helpful in selecting patients for preventive measures before RT and altering RT treatment. To date, prior studies only captured bodyweight at baseline visit and again at the end of treatment [10–12], without considering the downward trend of weight loss during RT period.

To fill current gaps in knowledge, we conducted a large-scale retrospective study of NPC patients treated with radical RT. The present study sought to (1) draw a downward trend of weight loss during RT; (2) identify the weight loss prognostic value on survival outcomes; and (3) demonstrate risk factors for weight loss among NPC patients.

Methods
Patient characteristics
The present study was a retrospective cohort study utilizing an NPC-specific database from Sun Yat-Sen University Cancer Center between January 2006 and October 2014. We included patients if they met the following criteria: (1) newly diagnosed non-disseminated NPC; (2) Karnosky performance score (KPS) ≥ 80; (3) no indication of distant metastases; (4) absent of secondary malignancy; (5) treated with radical intensity-modulated radiotherapy (IMRT); and (6) complete bodyweight information. This study was approved by the Institutional Review Board of Sun Yat-Sen University Cancer Center, and informed consent was obtained from all patients.

A total of 1149 patients were included in our study. The baseline assessment included full physical examination, fiberoptic nasopharyngoscopy, magnetic resonance imaging, computed tomography, abdominal ultrasonography, biochemistry profiling and hematology, whole body bone scan or 18F-fluorodeoxyglucose positron emission tomography and computed tomography. Real-time quantitative polymerase chain reaction was used to measure Epstein-Barr virus (EBV) DNA concentrations as previously described in detail [15]. Patients were staged based on the 7th edition of the American Joint Commission on Cancer (AJCC) staging system [16].

Radiotherapy and chemotherapy
All patients received radical IMRT in the current study. Dose prescribed to patients were (1) 66-70 Gy at 2.12-2.27 Gy/fraction to planning target volume (PTV) of nasopharyngeal gross tumor volume (GTVnx); (2) PTV of GTV of the metastatic lymph nodes (GTVnd) received 64-70 Gy; (3) high-risk clinical target volume (CTV1) received 60-63 Gy to PTV; and (4) low-risk clinical target volume (CTV2) received 50-56 Gy to PTV. During the study period, institutional guidelines recommended no chemotherapy for patients with stage I, and concurrent chemoradiotherapy +/- neoadjuvant/adjuvant chemotherapy for stages II to IVB, as defined by the 7th edition of AJCC staging system. Neoadjuvant or adjuvant chemotherapy consisted of cisplatin (60 mg/m2), docetaxel (60 mg/m2), and 5-fluorouracil (600 mg/m2/day over 120h), or cisplatin (80 mg/m2) plus 5-fluorouracil (800 mg/m2/day over 120h) or cisplatin (80 mg/m2) plus docetaxel (80 mg/m2) every 3 weeks for three cycles. Concurrent chemotherapy comprised of cisplatin (80 or 100 mg/m2) given in weeks one, four, and seven of RT, or cisplatin (40 mg/m2) given weekly during radiotherapy.

Data collection
Patients’ age, height, weight, sex, pre-therapy laboratory counts of serum lactate dehydrogenase (LDH), high sensitivity C-reactive protein (hs-CRP), plasma EBV DNA,
pathological types, clinical stage, and treatment type were extracted from medical records. Digital electronic scale (XiangShan, EB9871) was used to measure bodyweight to the nearest 0.1 kg in light garment and without shoes. We measured patients’ bodyweight at initiation of RT and every week during RT. Bodyweight before RT (WPre-RT) was measured at initiation of RT, and WRT1,2,3,4,5,6,7 (body weight at 1st, 2nd, 3rd, 4th, 5th, 6th, and 7th week of RT) was measured at each week of RT. The RT-PWL1,2,3,4,5,6,7 (percentage of weight loss at week 1, 2, 3, 4, 5, 6, 7 of RT) was calculated using the following equation: \((\text{W}_{\text{Pre-RT}} - \text{W}_{\text{RT1,2,3,4,5,6,7}}) / \text{W}_{\text{Pre-RT}} \times 100\%\).

Bodyweight before NAC (WPre-NAC) was also measured at initiation of NAC for patients who received NAC before RT. NAC-PWL was calculated using the following equation: \((\text{W}_{\text{Pre-NAC}} - \text{W}_{\text{Pre-RT}}) / \text{W}_{\text{Pre-NAC}} \times 100\%\).

At time of study, all patients were on 100% oral intake, where no type of enteral feeding tube or total parental nutrition were used.

**Follow-up and endpoints**

Patients were examined every 3 months during the first 2 years, and every 6 months for years three through five, and annually thereafter until death. Disease-free survival (DFS) was our primary endpoint, defined as time from treatment diagnos to documented recurrence of disease (either distant metastasis or locoregional disease recurrence) or mortality from any cause, whichever occurred first. Secondary endpoints consisted of (1) distant metastasis free survival (DMFS) (no documented distant metastasis); (2) locoregional relapse free survival (LRRFS) (no documented locoregional recurrence); and (3) overall survival (OS).

**Statistical methods**

In this study, we dichotomized the RT-PWL7 (percentage of weight loss at week 7 of RT) based on the optimal threshold: a RT-PWL7 of 5%, which was identified using the recursive partitioning analysis (RPA). Other variables such as host factors (e.g. age, gender, smoking history, hs-CRP, LDH, and plasma EBV DNA), treatment factors (e.g. treatment modality), and tumor factors (e.g. histology type, T stage, and N stage) were also grouped according to cutoff points from prior findings [17–19]. We first used the Kaplan-Meier method followed by the log-rank test to display the survival rate by the follow-up time and compare the difference in survival rates between the RT-PWL7 < 5% group and the RT-PWL7 ≥ 5% group. For each time-to-event outcome, we then developed univariate COX regression models to evaluate the association between the outcome and each of the independent variables, and included those with a \(P < 0.1\) into the multivariate COX regression model. Hazard ratios (HRs) from the multivariate COX regression models were reported to describe the potential impact of RT-PWL7 after controlling for confounders. Furthermore, we investigated the potential factors associated with RT-PWL7 using logistic regression models. All statistical tests and \(p\)-values were two-sided. Analyses were conducted in R version 4.1.0 (http://www.r-project.org/).

**Results**

**Patient characteristics**

Clinicopathological characteristics of the 1149 patients are shown in Table 1. The median age was 45 years (range, 10–78 years), and the male/female ratio was 3.5:1. The percentage of patients at stage I, II, III, and IVA-B were 2.1, 9.9, 53.7, and 34.3%, respectively. During treatment, 140 patients (12%) received no chemotherapy, 549 (48%) received NAC, and 1009 (88%) received concurrent chemotherapy. Only 48% (262/549) patients experienced weight loss during NAC, but up to 92% (1058/1149) of patients experienced weight loss during RT. The median follow-up time was 72.6 months (interquartile range [IQR], 54.6–85.8 months).

**Variation of bodyweight loss during treatment**

The median weight loss during NAC was 0.5 kg (IQR, 0 to 2.0 kg), and the median NAC-PWL was 1.1% (IQR, 0 to 3.3%). In contrast, the median weight loss during RT was 4.0 kg (IQR, 2.0 to 6.0 kg) and the median RT-PWL7 was 6.6% (IQR, 3.6 to 9.7%). We further outlined the downward trends of weight loss in the Fig. 1. Our results indicated RT-PWL remained largely unchanged in the first 2 weeks of RT, and then began to drop continuously at the following 5 weeks of RT (from 0 to 6.6%; at a percentage of about 1.3% weight loss per week).

**Prognostic value of bodyweight loss in patients with NPC**

Five-year and ten-year DFS, OS, DMFS, and LRRFS rates were 76.3 and 66.8%, 86.0 and 75.3%, 85.9 and 83.1%, and 93.2 and 92.7%, respectively. For the RT-PWL7, the optimal cutoff point for DFS among the entire group was 5.3% based on RPAs. Thus, a uniform cutoff point was selected at 5% (≤ 5% vs ≥ 5%) to classify patients into groups low RT-PWL7 and high RT-PWL7 for survival analysis. Overall, 65% (747/1149) of patients suffered ≥ 5% weight loss. When comparing survival between groups, our findings showed the high RT-PWL7 group had poorer ten-year DFS (61.2% vs 78.8%; \(P = 0.001\); Fig. 2A), OS (70.1% vs 86.6%; \(P < 0.001\); Fig. 2B), and DMFS (80.2% vs 88.5%; \(P = 0.007\); Fig. 2C) compared to low RT-PWL7 patients. No associated difference between groups for ten-year LRRFS (91.7% vs 94.3%; \(P = 0.173\); Fig. 2D) was observed. In multivariate analyses, RT-PWL7 ≥ 5% was an independent unfavorable prognostic factor for DFS (HR,
Table 1  Baseline patient characteristics according to rate of weight loss during radiotherapy

| Characteristic                              | Total (N = 1149)\(^a\) | No. (%) of patients by RT-PWL | P value |
|---------------------------------------------|--------------------------|-------------------------------|---------|
|                                             |                          | < 5% (n = 402, 35%) | ≥5% (n = 747, 65%) |
| Gender                                      |                          |                               | 0.826   |
| Male                                        | 892 (77.6)               | 314 (78.1)                   | 578 (77.4) |
| Female                                      | 257 (22.4)               | 88 (21.2)                    | 169 (22.6) |
| Age, years                                  |                          |                               | 0.665   |
| ≤45                                         | 594 (51.7)               | 204 (50.7)                   | 390 (52.2) |
| >45                                         | 555 (48.3)               | 198 (49.3)                   | 357 (47.8) |
| Histology (WHO)                             |                          |                               | 0.732   |
| Type I-II                                   | 35 (3.1)                 | 11 (2.7)                     | 24 (3.2) |
| Type III                                    | 1114 (96.9)              | 391 (97.3)                   | 723 (96.8) |
| Smoking history                             |                          |                               | 0.996   |
| No                                          | 807 (70.2)               | 282 (70.2)                   | 525 (70.3) |
| Yes                                         | 342 (29.8)               | 120 (29.9)                   | 222 (29.7) |
| T stage (7th edition)                       |                          |                               | 0.031   |
| T1                                          | 71 (6.2)                 | 32 (8.0)                     | 39 (5.2) |
| T2                                          | 185 (16.1)               | 69 (17.2)                    | 116 (15.5) |
| T3                                          | 627 (54.6)               | 226 (56.2)                   | 401 (53.7) |
| T4                                          | 266 (23.2)               | 75 (18.7)                    | 191 (25.6) |
| N stage (7th edition)                       |                          |                               | <0.001  |
| N0                                          | 128 (11.1)               | 59 (14.7)                    | 69 (9.2) |
| N1                                          | 448 (39.0)               | 177 (44.0)                   | 271 (36.3) |
| N2                                          | 399 (34.7)               | 118 (29.4)                   | 281 (37.6) |
| N3                                          | 174 (15.1)               | 48 (11.9)                    | 126 (16.9) |
| Overall stage                               |                          |                               | 0.001   |
| Stage I                                     | 24 (2.1)                 | 13 (3.2)                     | 11 (1.5) |
| Stage II                                    | 114 (9.9)                | 53 (13.2)                    | 61 (8.2) |
| Stage III                                   | 617 (53.7)               | 223 (55.5)                   | 394 (52.7) |
| Stage IVA-B                                 | 394 (34.3)               | 113 (28.1)                   | 281 (37.6) |
| hs-CRP, g/mL\(^b\)                          |                          |                               | 0.536   |
| <1.0                                        | 363 (31.6)               | 133 (33.1)                   | 230 (30.8) |
| 1.0-3.0                                      | 370 (32.2)               | 132 (32.8)                   | 238 (31.9) |
| ≥3.0                                        | 416 (36.2)               | 137 (34.1)                   | 279 (37.4) |
| LDH, U/L\(^b\)                              |                          |                               | 0.095   |
| <245                                        | 1058 (92.1)              | 378 (94.0)                   | 680 (91.0) |
| ≥245                                        | 91 (7.9)                 | 24 (6.0)                     | 67 (9.0) |
| EBV DNA, copy/mL\(^b\)                      |                          |                               | 0.006   |
| < 4000                                      | 766 (66.7)               | 289 (71.9)                   | 477 (63.9) |
| ≥4000                                       | 383 (33.3)               | 113 (28.1)                   | 270 (36.1) |
| Treatment strategy                          |                          |                               | <0.001  |
| RT alone                                    | 140 (12.2)               | 81 (20.2)                    | 59 (7.9) |
| CCRT alone                                  | 460 (40.0)               | 126 (31.3)                   | 334 (44.7) |
| NAC+CCRT                                    | 549 (47.8)               | 195 (48.5)                   | 354 (47.4) |

Abbreviations: RT-PWL Percentage of weight loss during radiotherapy, hs-CRP High sensitivity C-reactive protein, LDH Lactate dehydrogenase, EBV Epstein-Barr virus, RT Radiotherapy, CCRT Concurrent chemoradiotherapy, NAC Neoadjuvant chemotherapy

\(^a\) Percentages may not add up to 100 due to rounding

\(^b\) All variables were measured before treatment
1.56; 95%CI, 1.19-2.03; \( P = 0.001 \), OS (HR, 1.54; 95%CI, 1.11-2.15; \( P = 0.011 \)), and DMFS (HR, 1.47; 95%CI, 1.03-2.10; \( P = 0.033 \)) (Table 2). The prognostic value of NAC-PWL for patients that received NAC was assessed as well. Consistent with RT-PWL, a uniform cutoff point of 5% (<5% versus ≥5%) was selected for survival analysis. In contrast, the ten-year rates of DFS (59.3% vs. 63.9%; \( P = 0.325 \); Fig. 3A), DMFS (69.1% vs. 70.9%; \( P = 0.373 \); Fig. 3B), OS (80.3% vs. 80.3%; \( P = 0.781 \); Fig. 3C), and LRFS (91.4% vs. 91.7%; \( P = 0.812 \); Fig. 3D) were comparable between patients who experienced NAC-PWL < 5% and those who experienced NAC-PWL ≥ 5%.

Correlation between RT-PWL and clinicopathological characteristics

Table 1 presents the correlations between clinicopathological characteristics and RT-PWL. High RT-PWL patients were more likely to have advanced TNM stage (advanced T, N, and/or overall stage) (\( P < 0.05 \) for all). With respect to treatment strategy, the proportion receiving RT alone among the low RT-PWL group was associated with higher receipt compared with high RT-PWL group (20.2% versus 7.9%; \( P < 0.001 \)). Factors associated with development of high or low RT-PWL were analyzed. After multivariate analysis, treatment modality, plasma EBV DNA, and N stage remained associated with RT-PWL (\( P < 0.05 \) for all; Table 3). Patients treated with RT alone had the lowest risk with development of weight loss during RT. In contrast, CCRT alone or NAC followed by CCRT had a significantly strong correlation with the development of high weight loss (\( P < 0.05 \) for all). Moreover, patients with advanced N stage (N2-3) were more likely to suffer high weight loss than patients with early N stage (N1-2) (OR, 1.52; 95% CI, 1.12–1.94; \( P = 0.005 \)) during RT.

Discussion

To our knowledge, this is the longest follow-up analysis for investigating the downward trend in weight loss during treatment among NPC patients. Weight loss was more often observed in the RT period than NAC period. Although the prognostic value of NAC-PWL for NPC was not observed, RT-PWL ≥ 5% was significantly associated with inferior ten-year DFS, OS, and DMFS for NPC patients. Further analysis revealed that bodyweight remained largely unchanged during RT for the first 2 weeks, and dropped continuously at the following 5 weeks of RT.

Numerous studies [20, 21] have confirmed that weight loss is correlated with poor prognosis among individuals diagnosed with head and neck cancer, including NPC [10, 11]. Results from our study aligned closely with prior findings [10, 11]. There are several potential reasons for these findings. First, critical weight loss may result in loosening of posture fixation, inaccurate radiation field, and significant dosimetric change during RT [22]. Second, reduction in treatment tolerance and radiotherapy breaks could result from weight loss, thus influencing
therapeutic efficacy [23, 24]. Third, weight loss is often used as a tool for assessment of newly developed malnutrition, which contributes to weakness in immunity defense mechanism, such as cellular and humoral immunity, phagocyte function, and anatomic barriers. Hence, increasing infection susceptibility and reduced response to malignancy [25, 26]. We must note that the present study failed to confirm the significant impact of RT-PWL7 in locoregional control. These finding are reasonable as excellent locoregional control (5-year LRFFS > 90%) is expected for IMRT, therefore actual impact of weight loss on LRFFS would be limited [27, 28].

Previous studies reported that weight loss ≥5% during RT was associated with poor survival [12, 23]. Consistent with previous studies, our results indicated RT-PWL7 ≥5% was associated with poor DFS, OS, and DMFS. However, Du et al [11] recently assessed weight loss during the entire treatment procedure and observed weight loss ≥10% was an indicator for likelihood of metastasis and overall survival. This inconsistency might be due to some obvious differences between the definition of weight loss in the study by Du et al and the current study. The weight loss during NAC (NAC-PWL) or RT period (RT-PWL) was evaluated separately in our study. However, compared with our study, the weight loss during the entire treatment (including NAC and RT period) was evaluated together by Du et al, which may increase the span of weight loss. Overall, the impact of

![Fig. 2 Comparison between the RT-PWL7 < 5% group and the RT-PWL7 ≥ 5% group for disease-free survival, overall survival, distant metastasis-free survival, and locoregional relapse-free survival. RT-PWL7, percentage of weight loss at week 7 of radiotherapy (RT)](image-url)
weight loss on prognosis of NPC can be determined in the present study.

During treatment, numerous factors may influence weight loss among cancer patients [9, 11]. We observed that patients treated with CCRT alone or NAC plus CCRT were more likely to suffer high weight loss during RT when compared with those treated with RT alone. This result was similar with findings by Qiu et al [9] and Du et al [11]. Although encouraging results attained by multimodal therapy for NPC, acute toxicities are more likely to occur during high-intensity chemoradiotherapy [9], including severe oral mucositis, nausea, and vomiting. In the present study, advanced N stage was associated with high weight loss, which was consistent with findings by Du and colleagues. A patient with advanced N stage might receive a higher radiation dose of oropharynx and more aggressive cisplatin-based chemotherapy, potentially exacerbating oropharyngeal pain and oral mucositis. Subsequently, severe oropharyngeal pain and oral mucositis can make eating difficult and lead to weight loss. Other risk factors including radiation technique and segmentation model are partly relevant to oral mucositis and weight loss. Since this research adopts the unified radiation technique and segmentation model, we did not include the above factors for analysis.

Prior studies [10–12] primarily evaluated weight loss at a single time point, usually pre- or post-treatment. For this reason, limited knowledge exists about the dynamic change of weight loss during RT. Since weight loss is common among NPC patients, it is necessary to assess weight change over RT time, potentially providing a more complete understanding on the relationship between bodyweight and survival. Our results indicated that bodyweight remained generally unchanged in the

Table 2 Multivariate analysis of prognostic factors for patients with NPC (n = 1149)

| Endpoint | Variable | HR | 95% CI for HR | P* |
|----------|----------|----|--------------|----|
| DFS      | RT-PWL (< 5% vs ≥ 5%) | 1.56 | 1.19–2.03 | 0.001 |
|          | Age (< 45 vs > 45, years) | 1.36 | 1.08–1.71 | 0.010 |
|          | Gender (Male vs Female) | 1.18 | 0.91–1.53 | 0.215 |
|          | Pathology (Type I-II vs Type III) | 0.44 | 0.26–0.72 | 0.001 |
|          | T stage (T1-2 vs T3-4) | 1.62 | 1.16–2.27 | 0.005 |
|          | N stage (N0-1 vs N2-3) | 1.54 | 1.20–1.97 | 0.001 |
|          | EBV DNA (< 4000 vs ≥ 4000, copy/mL) | 1.50 | 1.12–2.01 | 0.007 |
|          | Treatment strategy (RT alone vs CCRT) | 0.75 | 0.48–1.17 | 0.200 |
|          | Treatment strategy (RT alone vs NAC + CCRT) | 0.84 | 0.54–1.32 | 0.455 |
| OS       | RT-PWL (< 5% vs ≥ 5%) | 1.54 | 1.11–2.15 | 0.011 |
|          | Age (< 45 vs > 45, years) | 1.57 | 1.17–2.10 | 0.002 |
|          | Pathology (Type I-II vs Type III) | 0.37 | 0.21–0.66 | 0.001 |
|          | T stage (T1-2 vs T3-4) | 1.84 | 1.20–2.81 | 0.005 |
|          | N stage (N0-1 vs N2-3) | 1.72 | 1.26–2.81 | 0.001 |
|          | Smoking history (No vs Yes) | 1.26 | 0.93–1.70 | 0.131 |
|          | LDH (< 245 vs ≥ 245, U/L) | 1.27 | 0.80–2.03 | 0.308 |
|          | EBV DNA (< 4000 vs ≥ 4000, copy/mL) | 1.54 | 1.08–2.21 | 0.018 |
| DMFS     | RT-PWL (< 5% vs ≥ 5%) | 1.47 | 1.03–2.10 | 0.033 |
|          | Age (< 45 vs > 45, years) | 1.43 | 1.04–1.96 | 0.026 |
|          | Pathology (Type I-II vs Type III) | 0.55 | 0.27–1.13 | 0.104 |
|          | T stage (T1-2 vs T3-4) | 1.41 | 0.92–2.18 | 0.118 |
|          | N stage (N0-1 vs N2-3) | 1.99 | 1.41–2.80 | < 0.001 |
|          | Smoking history (No vs Yes) | 1.37 | 0.99–1.90 | 0.055 |
|          | LDH (< 245 vs ≥ 245, U/L) | 1.33 | 0.82–2.16 | 0.247 |
|          | EBV DNA (< 4000 vs ≥ 4000, copy/mL) | 2.01 | 1.23–3.30 | 0.006 |
| LRRFS    | Pathology (Type I-II vs Type III) | 0.31 | 0.14–0.72 | 0.006 |
|          | Smoking history (No vs Yes) | 0.56 | 0.31–1.01 | 0.056 |
|          | Treatment strategy (RT alone vs CCRT) | 4.63 | 1.11–19.36 | 0.036 |
|          | Treatment strategy (RT alone vs NAC + CCRT) | 4.86 | 1.17–20.15) | 0.029 |

Abbreviations: RT-PWL Percentage of weight loss during radiotherapy, HR Hazard ratio, 95% CI 95% confidence interval, DFS Disease-free survival, OS Overall survival, DMFS Distant metastasis-free survival, LRRFS Locoregional relapse-free survival, LDH Lactate dehydrogenase, EBV Epstein-Barr virus.

* P values were calculated using an adjusted Cox proportional hazards model.
first 2 weeks of RT, and then began to drop relatively stable in the next 5 weeks of RT. The following reasons may explain the observed results. First, the oral mucous membrane reaction of patients is mild, and diet is less affected in the first 2 weeks of RT. With the increasing number of RT, weight loss is gradually accelerated due to oral mucositis, aggravated swallowing pain, and decreased treatment tolerance [4].

Several limitations must be noted. First, we failed to collect pre-existing nutrition status of the patients, which may confound the main findings of this research. Further studies are needed to collect pre-existing nutrition status in nutrition analysis. Second, we lacked detailed information on dietary habit, food intake, and nutritional status. However, during the study period, no standard criteria for nutritional support in patients undergoing RT has been established. Third, due to the lack of date, we couldn’t conduct the analysis of survival outcome against patients who required nutritional support (nasogastric tube feeding or gastrostomy feeding) and those who did not. Fourth, various treatment strategies (i.e., RT alone, CCRT alone, and NAC plus CCRT) may confound the optimal threshold of RT-PWL. Nevertheless, all treatment strategies included in our study were in line with National Comprehensive Cancer Network guidelines. Additionally, the adverse impact of weight loss on prognosis of NPC was still determined in our study. Last but not least, the data used in this study derived from only

![Comparison between the NAC-PWL < 5% group and the NAC-PWL ≥ 5% group for A disease-free survival, B overall survival, C distant metastasis-free survival, and D locoregional relapse-free survival. NAC-PWL: percentage of weight loss during neoadjuvant chemotherapy (NAC).](image)
Table 3 Multivariate analysis of prognostic factors for the development of high RT-PWL in patients with NPC

| Variable     | OR   | 95% CI for OR | P value* |
|--------------|------|---------------|----------|
| T stage      |      |               |          |
| T1-2         | Reference |           |          |
| T3-4         | 1.01 | 0.74–1.38     | 0.955    |
| N stage      |      |               |          |
| N0-1         | Reference |           |          |
| N2-3         | 1.52 | 1.12–1.94     | 0.005    |
| LDH, U/Lb    |      |               |          |
| <245         | Reference |           |          |
| ≥245         | 1.38 | 0.83–2.29     | 0.232    |
| EBV DNA, copy/mLb |      |               |          |
| <4000        | Reference |           |          |
| ≥4000        | 1.43 | 1.04–1.96     | 0.034    |
| Treatment    |      |               |          |
| RT alone     | Reference |           |          |
| CCRT alone   | 3.29 | 2.18–4.96     | <0.001   |
| NAC+CCRT     | 2.03 | 1.32–3.13     | 0.001    |

Abbreviations: OR Odds ratio, 95% CI 95% confidence interval, LDH Lactate dehydrogenase, EBV Epstein-Barr virus, RT Radiotherapy, CCRT Concurrent chemoradiotherapy, NAC + CCRT Neoadjuvant chemotherapy plus concurrent chemoradiotherapy

*P values were calculated using logistic regression models

**All variables were measured before treatment

one institution, where a large proportion of physicians have expertise in diagnosing and treating NPC. Future studies that incorporate external validation are needed.

Conclusions
In conclusion, the downward trend of weight loss at every week during RT was outlined, and, after the end of RT, the optimal threshold for RT-PWL adversely impacting NPC prognosis was 5%. Further research is needed on limiting weight loss during RT under 5% in clinical practice as a result of the detrimental impact of RT-PWL≥5% on survival outcomes. Additionally, treatment strategy, plasma EBV DNA, and N stage were associated with weight loss. These findings would be helpful in selecting patients for preventive measures before RT.

Abbreviations
NPC: Nasopharyngeal carcinoma; RT: Radiotherapy; KPS: Karnofsky performance score; IMRT: Intensity-modulated radiotherapy; EBV: Epstein-Barr virus; AJCC: American Joint Commission on Cancer; PTV: Planning target volume; GTVnc: Nasopharyngeal gross tumor volume; GTVd: GTV of the metastatic lymph nodes; CTV1: High-risk clinical target volume; CTV2: Low-risk clinical target volume; NAC: Neoadjuvant chemotherapy; CCRT: Concurrent chemoradiotherapy; LDH: Lactate dehydrogenase; hs-CRP: High sensitivity C-reactive protein; WPre-RT: Bodyweight before RT; NAC-PWL: Percentage of weight loss during neoadjuvant chemotherapy; RT-PWL: Percentage of weight loss during radiotherapy; RT-PWL7: Percentage of weight loss at week 7 of radiotherapy; DFS: Disease-free survival; DMFS: Distant metastasis-free survival; OS: Overall survival; LRRFS: Locoregional relapse-free survival; RPAs: Recursive partitioning analyses.

Acknowledgements
The authors acknowledge the contributions of all study participants.

Authors’ contributions
Data collection and writing original draft was performed by JYN, XTL, and MDM. Formal analysis, reviewing and editing was done by YJJ and JC. JYN and XTL participated in project administration and study design. Study design was conceived and designed by XLP and HWZ. Prior to submission of this manuscript, all authors have reviewed and approved.

Funding
This work was supported by grants from the Science and Technology Program of Guangdong, China (2020A1515111075; 2021A1515220128), National Natural Science Foundation of China (81901699), Excellent Young Researchers Program of the 5th Affiliated Hospital of SYSU (WYXYQN-2021015), and Investigator Initiated Clinical Trial foundation of the 5th Affiliated Hospital of SYSU (YNZZ2021-04). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
The datasets analyzed during the current study are available in the Research Data Deposit (RDD) public platform www.researchdata.org.cn, with the approval RDD number of RDDA2019001296. The raw dataset is available from the corresponding author upon reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the Institutional Review Board of Sun Yat-sen University Cancer Center, and complied with the 2016/679 General Regulation on Personal Data Protection regarding the use of anonymised population data. As the current study was a retrospective assessment of routine data, the ethics committee of our Cancer Center waived the need for individual informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1VIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, China. The Cancer Center of the Fifth Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Biomedical Imaging, Zhuhai 519060, Guangdong, China. 2State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong, China. 3Department of Anaesthesiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou 510060, Guangdong, China.

Received: 8 December 2020 Accepted: 17 April 2022 Published online: 06 May 2022

References
1. Wee JT, Ha TC, Loong SL, Qian CN. Is nasopharyngeal cancer really a “Cantonese cancer”? Chin J Cancer. 2010;29(5):517–26.
2. Mao YP, Tang LL, Chen L, Sun Y, Qi ZY, Zhou GQ, et al. Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy. Chin J Cancer. 2016;35(1):103.

3. Sun XS, Liu SL, Luo MJ, Li XZ, Chen QY, Guo SS, et al. The association between the development of radiation therapy, image technology, and chemotherapy, and the survival of patients with nasopharyngeal carcinoma: a cohort study from 1990 to 2012. Int J Radiat Oncol Biol Phys. 2019;105(3):581–90.

4. Trotti A, Bellim LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66(3):253–62.

5. Wu SX, Cui TT, Zhao C, Pan JJ, Xu BY, Tian Y, et al. A prospective, randomized, multi-center trial to investigate Actovegin in prevention and treatment of acute oral mucositis caused by chemoradiotherapy for nasopharyngeal carcinoma. Radiother Oncol. 2010;97(1):113–8.

6. Luo DH, Hong MH, Guo L, Cao KJ, Deng MQ, Mo HY. Analysis of oral mucositis risk factors during radiotherapy for nasopharyngeal carcinoma patients and establishment of a discriminant model. Ai Zheng. 2005;24:850–4.

7. Nishioha T, Shirato H, Arimoto T, Kaneko M, Kitahara T, Oomori K, et al. Reduction of radiation-induced xerostomia in nasopharyngeal carcinoma using CT simulation with laser patient marking and three-field irradiation technique. Int J Radiat Oncol Biol Phys. 1997;38(4):705–12.

8. Li G, Jiang XY, Qiu B, Shen LJ, Chen C, Xia YF. Vicious circle of acute radiation toxicities and weight loss predicts poor prognosis for nasopharyngeal carcinoma patients receiving intensity modulated radiotherapy. J Cancer. 2017;8(5):852–8.

9. Qiu C, Yang N, Tian G, Liu H. Weight loss during radiotherapy for nasopharyngeal carcinoma: a prospective study from northern China. Nutr Cancer. 2011;63(6):873–9.

10. Zeng Q, Shen LJ, Guo X, Guo XM, Qian CN, Wu PH. Critical weight loss predicts poor prognosis in nasopharyngeal carcinoma. BMC Cancer. 2016;16:169.

11. Du XJ, Tang LL, Mao YP, Guo R, Sun Y, Lin AH, et al. Value of the prognostic nutritional index and weight loss in predicting metastasis and long-term mortality in nasopharyngeal carcinoma. J Transl Med. 2015;13:364.

12. Shen LJ, Chen C, Li BF, Gao J, Xia YF. High weight loss during radiation treatment changes the prognosis in under-/normal weight nasopharyngeal carcinoma patients for the worse: a retrospective analysis of 2433 cases. PLoS One. 2013;8(7):e69866.

13. Ho RF, Marchant T, Moore C, Webster G, Rowbottom C, Penington H, et al. Monitoring dosimetric impact of weight loss with kilovoltage (KV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy. Int J Radiat Oncol Biol Phys. 2012;82:e375–82.

14. Jensen AD, Nill S, Huber PE, Bendl R, Debus J, Münter MW. A clinical concept for interfractional adaptive radiation therapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys. 2012;82:590–596.

15. Yao JJ, Lin LN, Jin YN, Wang SY, Zhang WJ, Zhang F, et al. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA. Cancer Sci. 2017;108(8):1640–7.

16. Edge SB, Compton CC. The American joint committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.

17. Zhou GQ, Tang LL, Mao YP, Chen L, Li WF, Sun Y, et al. Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis. Int J Radiat Oncol Biol Phys. 2012;82(3):e539–65.

18. Allin KH, Bjoersen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009;27:2217–24.

19. Tang LJ, Li CF, Li J, Chen WH, Chen QY, Yuan LX, et al. Establishment and validation of prognostic nomograms for endemic nasopharyngeal carcinoma. J Natl Cancer Inst. 2015;108(1). https://doi.org/10.1377/jnci.jnj.008860.

20. Baxi SS, Schwartz E, Jones LW. A review of weight loss and sarcopenia in patients with head and neck cancer treated with chemoradiation. Cancers Head Neck. 2016;1:9. https://doi.org/10.1186/s41199-016-0010-0.

21. Langius JA, Twisk J, Kampman M, Doornaert P, Kramer MH, Weijis PJ, et al. Prediction model to predict critical weight loss in patients with head and neck cancer during (chemo)radiotherapy. Oral Oncol. 2016;52:91–6.

22. Chen C, Fei Z, Chen L, Bai P, Lin X, Pan J. Will weight loss cause significant dosimetric changes of target volumes and organs at risk in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy? Med Dosim. 2014;39(1):34–42.

23. Kubkic I, Olson K, Jha N, Scrimger R, Parliament M, McCargar L, et al. Clinical determinants of weight loss in patients receiving radiation and chemoradiation for head and neck cancer: a prospective longitudinal view. Head Neck. 2013;35(5):695–703.

24. Yao JJ, Zhang F, Gao TS, Zhang WW, Lawrence WR, Zhu BT, et al. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a big-data intelligence platform-based analysis. Radiother Oncol. 2019;132:178–87.

25. Datema FR, Ferrier MB, Baetenburg de Jong R]. Impact of severe malnutrition on short-term mortality and overall survival in head and neck cancer. Oral Oncol. 2011;47(9):910–4.

26. O’Shea D, Cawood TJ, O’Farrelly C, Lynch L. Natural killer cells in obesity: impaired function and increased susceptibility to the effects of cigarette smoke. PLoS One. 2010;5(1):e68660.

27. Sun X, Su S, Chen C, Han F, Zhao C, Xiao W, et al. Long-term outcomes of intensity-modulated radiotherapy for 888 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2014;110(3):398–403.

28. Yao JJ, Qi ZY, Liu ZG, Jiang GM, Xu XW, Chen SY, et al. Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a big-data intelligence platform-based analysis. Radiother Oncol. 2019;137:137–44.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.